Opendata, web and dolomites

PDX-PC SIGNED

Elucidation of tumour cell plasticity mechanisms associated to treatment in metastatic prostate cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PDX-PC project word cloud

Explore the words cloud of the PDX-PC project. It provides you a very rough idea of what is the project "PDX-PC" about.

optimal    mortality    clinicians    follow    regimens    signatures    responsible    pdx    models    outcomes    multidisciplinary    predictive    cell    metastatic    treatment    liquid    blocked    costly    xenografts    rna    subsequent    treatments    clinical    survive    tissues    despite    reprogram    heterogeneity    few    absence    resistance    causing    mechanisms    individualized    led    responding    ups    prevent    analysed    initially    prostate    choices    tumour    increment    plasticity    declined    rate    multiple    elucidate    validated    pc    decisions    clinic    cells    options    sequencing    last    guide    undergoing    economic    highlights    themselves    discover    fact    preserve    therapy    men    setting    cancer    disease    circulating    free    patients    initial    vivo    dna    burden    benefit    unnecessary    approved    therapeutic    accounts    prevalence    worldwide    malignancies    biomarkers    therapies    bioinformatics    sequences    biopsy    evolution    patient    durable    curative    molecular   

Project "PDX-PC" data sheet

The following table provides information about the project.

Coordinator
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER 

Organization address
address: CALLE ROSSELLO 149 PUERTA BJS
city: BARCELONA
postcode: 8036
website: http://www.idibaps.org/en_index.html

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 166˙202 €
 EC max contribution 166˙202 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-GF
 Starting year 2019
 Duration (year-month-day) from 2019-09-16   to  2021-09-15

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) coordinator 166˙202.00
2    MONASH UNIVERSITY AU (VICTORIA) partner 0.00

Map

 Project objective

Prostate cancer (PC) is among the top five leading malignancies causing cancer mortality worldwide. Increased prevalence and declined mortality rate have led to an increment in follow-ups with a significant rise in the economic burden. In the last few years, several new options for metastatic disease have been approved leading to clinicians to have multiple choices of therapy sequences. However, not all patients initially respond and most of them eventually develop resistance. The ability of tumour cells to reprogram themselves and survive despite the blocked targets (tumour cell plasticity) may accounts for the absence of durable responses. In addition, the fact that initial treatments may affect the potential benefit of subsequent treatments highlights the need to discover predictive biomarkers for optimal treatment selection, allowing early changes in treatment for non-responding patients. This multidisciplinary project aims to elucidate the molecular mechanisms responsible for tumour cell plasticity associated to treatment response in metastatic PC. Patient-derived xenografts (PDX) in vivo models will be used, since they preserve molecular heterogeneity and therapeutic response observed in the clinic. They will be treated under different regimens. Tumour tissues will be analysed by RNA sequencing before and after treatment. Bioinformatics analysis will be used to establish molecular signatures of treatment response that will be validated in liquid biopsy (circulating tumour cells and cell free DNA) from metastatic PC patients undergoing different treatments. PDX-PC will provide a better understanding of the molecular evolution of the disease that will contribute to design more specific and individualized treatments. In the setting of non-curative therapy, the implementation of such molecular findings at clinical practice may help to guide treatment decisions, improve outcomes, and prevent unnecessary side effects and costly therapies in men with metastatic PC.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PDX-PC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PDX-PC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More